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INDOXYL SULFATE SERUM LEVEL IN CHRONIC RENAL FAILURE PATIENTS
DETECTED USING FLUORESCENCE-HPLC
Chuan Zou, Fuhua Lu, Yuchi Wu, Qizhan Lin, Xusheng Liu
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.ss
Indoxyl sulfate (IS) is a protein-bound typical uremic toxin that
accumulates in patients with impaired kidney function. The laboratory
methods used to quantify serum concentrations of IS require
improvement. We report an optimal, cost-effective alternative to the
methods currently used.The methods is as follows: serum samples were
extracted and deproteinized using acetonitrile and then further puriﬁed
using dichloromethane. The samples were then analyzed using high-
performance liquid chromatography (HPLC) with a ﬂuorescence detector at
a ﬂow rate of 1.0 mL/min. The isocratic mobile phase consisted of
acetonitrile0.2% (V/V) triﬂuoroacetic acid in phosphate buffered saline,
pH 2.5 (8:92, V/V). Detector settings were lex 280 nm/lem 390 nm. Under
the indicated conditions, IS was well separated. The retention time was
approximately 6.5970.11 min. The results of the precision and
reproducibility tests were o3%, and the recovery rate was greater than
95%,(98.4473.21%).
In conclusion, HPLC with a ﬂuorescence detector is a simple, sensitive,
and reliable method for quantifying IS concentration in the serum of
patients with chronic renal failure.
http://dx.doi.org/10.1016/j.krcp.2012.04.36340
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Vascular changes characterized by calciﬁcation of either intima or media
result in arterial stiffness and cardiac hypertrophy, especially in
hemodialyais patients with secondary hyperparathyroidism. The purpose
of this study is to evaluate the effects of cinacalcet on arterial compliance
and cardiac hypertrophy. We studied 14 patients with ESRD who had high
levels of intact PTH (iPTH, 4300 pg/mL) and of corrected serum calcium
(cCa, 49.0 mg/dL) with cinacalcet over 20-week period prospectively.
After 20 weeks treatment, we performed ﬂow-mediated dialation (FMD),
cadio-ankle vascular index (CAVI) and echocardiographic analyses. Twenty
weeks cinaclacet treatment signiﬁcantly decreased blood levels of iPTH
(628.27250.8 vs. 251.77237.4 pg/ml, po0.01), calcium
(9.770.7 vs.8.770.6 mg/dl, Po0.01), phosphorus (6.871.3 vs.
5.071.4 mg/dl, Po0.01), calcium x phosphorus product (64.8715.4 vs.
43.5714.9, Po0.01) and 25(OH) vitamin D (9.973.4 vs. 8.272.7 ng/mL,
Po0.05). There were no signiﬁcant changes in LV mass, the ejection
fraction and fractional shortening. In contrast, cinacalcet signiﬁcantly
improved FMD (8.672.9 vs. 14.372.8%, Po0.01) and enhanced CAVI
(8.872.3 vs. 7.672.4, Po0.05), respectively. In conclusion, cinacalcet
treatment in hemodialysis patients with secondary hyperparathyroidism
ameliorates endothelial dysfunction and arterial compliance.
http://dx.doi.org/10.1016/j.krcp.2012.04.36441
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Recent studies have shown that brain-derived neurotrophic factor
(BDNF) is associated with neurotoxic, inﬂammatory and nutritional status.
The purpose of this study is to investigate the changes in plasma BDNF
concentration that were induced by chronic uremic condition. Using an
enzyme-linked immunosorbent assay (ELISA), we measured peripheralBDNF levels in pre-hemodialysis (pre-HD), peritoneal dialysis (PD) patients
and in a control group. The plasma BDNF concentrations of pre-HD, PD
patients were signiﬁcantly higher compared with those of controls
(856.37879.1, 1167.97647.5 versus 403.17288.9 pg/ml, respectively).
The plasma BDNF in dialysis patients was positively correlated with high-
sensitivity C reactive protein (hs-CRP) and with serum albumin negatively.Plasma BDNF hs-CRP Albuminr p r pPre-HD 0.321 0.025 -0.298 0.021
PD 0.414 0.070 -0.527 0.008
Pre-HD þ PD 0.446 0.001 -0.453 0.001In conclusion, BDNF might plays some role in the neurotoxicity of
uremia and associated with inﬂammation and malnutrition in dialysis
patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.36542
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In the course of chronic renal failure, low protein-diets allow better
control of metabolic disorders and may delay the start of renal
replacement therapy (RRT). However, concerns exist that a very low
protein diet supplemented with ketoacids (sVLPD) worsens survival after
starting RRT. To evaluate whether a prolonged sVLPD regimen may affect
all-cause mortality during the following RRT period, we studied time to all-
cause death during RRT in patients previously followed in renal clinics
either treated with sVLPD (sVLPD group, n¼184, age 67718 yrs) or not
(CKD group, n¼334, age 66714 yrs). A Control group including 9,092
patients (age 66714 yrs) was selected from the Italian dialysis &
transplantation registry (RIDT).
In sVLPD, CKD and Control groups, the prevalence of an history of
cardiovascular disease was 41, 31, 25% and of diabetes was 18%, 31%, 17%,
respectively; the median follow-up time in RRT (36, 32, 36 months) did not
differ among groups.Cumulative survival was similar in sVLPD and CKD
groups (p¼0.638), but signiﬁcantly higher than in the Control group (Long-
rank test, 20,62; po0.0001). These results persisted in the Cox model
adjusted for age, gender, diabetes, history of cardiovascular disease; as
compared with controls, the HRs [95% CI] for death were 0.57 [0.450.74]
(p¼0.0001) in sVLPD and 0.65 [0.530.80] (p¼0.001) in CKD group. Due
to age interaction with survival in sVLPD (p¼0.024), HRs for death reduced
to 0.34 [0.160.73] and 0.58 [0.370.92] in sVLPD and CKD pts o70 yrs.
In conclusion, prescription of sVLPD during the conservative phase of
chronic renal failure does not worsen, or even improves, survival after
starting RRT. This survival advantage is more evident in patients younger
than 70 years.
http://dx.doi.org/10.1016/j.krcp.2012.04.366
